Stryker Corporation (SYK) Position Maintained by Taylor Wealth Management Partners
Taylor Wealth Management Partners maintained its stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the SEC. The fund owned 750 shares of the medical technology company’s stock at the end of the second quarter. Taylor Wealth Management Partners’ holdings in Stryker Corporation were worth $104,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Bollard Group LLC increased its stake in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock valued at $109,000 after buying an additional 3 shares in the last quarter. Assetmark Inc. increased its stake in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares in the last quarter. Blue Chip Partners Inc. increased its stake in shares of Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock valued at $234,000 after buying an additional 6 shares in the last quarter. Guardian Life Insurance Co. of America increased its stake in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares in the last quarter. Finally, Baystate Wealth Management LLC increased its stake in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares in the last quarter. Institutional investors own 73.99% of the company’s stock.
Shares of Stryker Corporation (NYSE SYK) traded up 0.19% during trading on Friday, reaching $144.18. 847,631 shares of the company’s stock were exchanged. The firm has a market cap of $53.93 billion, a price-to-earnings ratio of 32.18 and a beta of 0.80. Stryker Corporation has a 12 month low of $106.48 and a 12 month high of $148.84. The stock has a 50-day moving average price of $143.71 and a 200 day moving average price of $135.51.
Stryker Corporation (NYSE:SYK) last released its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. During the same quarter last year, the firm posted $1.39 earnings per share. The business’s revenue was up 6.1% compared to the same quarter last year. On average, analysts forecast that Stryker Corporation will post $6.50 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be paid a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. Stryker Corporation’s payout ratio is 37.95%.
WARNING: This story was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://theolympiareport.com/2017/08/12/stryker-corporation-syk-position-maintained-by-taylor-wealth-management-partners.html.
Several brokerages have recently commented on SYK. BidaskClub downgraded shares of Stryker Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Jefferies Group LLC reiterated a “hold” rating and issued a $132.00 target price on shares of Stryker Corporation in a report on Friday, June 30th. Barclays PLC reiterated a “sell” rating and issued a $133.00 target price on shares of Stryker Corporation in a report on Thursday, April 27th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $148.00 target price on shares of Stryker Corporation in a report on Monday, April 17th. Finally, Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Stryker Corporation and gave the company a “hold” rating in a report on Friday, July 28th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. Stryker Corporation currently has an average rating of “Hold” and an average target price of $144.03.
In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the sale, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David Floyd sold 19,305 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,810 shares of company stock worth $4,754,958. Insiders own 7.40% of the company’s stock.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.